Integrated genomic characterization of endometrial carcinoma

Cancer Genome Atlas Research Network, Cyriac Kandoth, Nikolaus Schultz, Andrew D Cherniack, Rehan Akbani, Yuexin Liu, Hui Shen, A Gordon Robertson, Itai Pashtan, Ronglai Shen, Christopher C Benz, Christina Yau, Peter W Laird, Li Ding, Wei Zhang, Gordon B Mills, Raju Kucherlapati, Elaine R Mardis, Douglas A Levine

Abstract

We performed an integrated genomic, transcriptomic and proteomic characterization of 373 endometrial carcinomas using array- and sequencing-based technologies. Uterine serous tumours and ∼25% of high-grade endometrioid tumours had extensive copy number alterations, few DNA methylation changes, low oestrogen receptor/progesterone receptor levels, and frequent TP53 mutations. Most endometrioid tumours had few copy number alterations or TP53 mutations, but frequent mutations in PTEN, CTNNB1, PIK3CA, ARID1A and KRAS and novel mutations in the SWI/SNF chromatin remodelling complex gene ARID5B. A subset of endometrioid tumours that we identified had a markedly increased transversion mutation frequency and newly identified hotspot mutations in POLE. Our results classified endometrial cancers into four categories: POLE ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high. Uterine serous carcinomas share genomic features with ovarian serous and basal-like breast carcinomas. We demonstrated that the genomic features of endometrial carcinomas permit a reclassification that may affect post-surgical adjuvant treatment for women with aggressive tumours.

Conflict of interest statement

The author declares no competing financial interests.

Figures

Figure 1. SCNAs in endometrial carcinomas.
Figure 1. SCNAs in endometrial carcinomas.
a, Tumours were hierarchically clustered into four groups based on SCNAs. The heat map shows SCNAs in each tumour (horizontal axis) plotted by chromosomal location (vertical axis). Chr., chromosome. b, Kaplan–Meier curves of progression-free survival for each copy-number cluster. PowerPoint slide
Figure 2. Mutation spectra across endometrial carcinomas.
Figure 2. Mutation spectra across endometrial carcinomas.
a, Mutation frequencies (vertical axis, top panel) plotted for each tumour (horizontal axis). Nucleotide substitutions are shown in the middle panel, with a high frequency of C-to-A transversions in the samples with POLE exonuclease mutations. CN, copy number. b, Tumours were stratified into the four groups by (1) nucleotide substitution frequencies and patterns, (2) MSI status, and (3) copy-number cluster. SNV, single nucleotide variant. c, POLE-mutant tumours have significantly better progression-free survival, whereas copy-number high tumours have the poorest outcome. d, Recurrently mutated genes are different between the four subgroups. Shown are the mutation frequencies of all genes that were significantly mutated in at least one of the four subgroups (MUSiC, asterisk denotes FDR < 0.05). PowerPoint slide
Figure 3. Gene expression across integrated subtypes…
Figure 3. Gene expression across integrated subtypes in endometrial carcinomas.
a, Supervised analysis of ∼1,500 genes significantly associated with integrated subtypes. b, Heat map of protein expression clusters, supervised by integrated subtypes. Samples are in columns; genes or proteins are in rows. PowerPoint slide
Figure 4. Pathway alterations in endometrial carcinomas.
Figure 4. Pathway alterations in endometrial carcinomas.
a, The RTK/RAS/β-catenin pathway is altered through several mechanisms that exhibit mutually exclusive patterns. Alteration frequencies are expressed as a percentage of all cases. The right panel shows patterns of occurrence. b, The PI(3)K pathway has mutually exclusive PIK3CA and PIK3R1 alterations that frequently co-occur with PTEN alterations in the MSI and copy-number low subgroups. c, Heat map display of top 1,000 varying pathway features within PARADIGM consensus clusters. Samples were arranged in order of their consensus cluster membership. The genomic subtype for each sample is displayed below the consensus clusters. PowerPoint slide
Figure 5. Genomic relationships between endometrial serous-like,…
Figure 5. Genomic relationships between endometrial serous-like, ovarian serous, and basal-like breast carcinomas.
a, SCNAs for each tumour type. b, Frequency of genomic alterations present in at least 10% of one tumour type. PowerPoint slide

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013;63:11–30. doi: 10.3322/caac.21166.
    1. Fleming GF, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2004;22:2159–2166. doi: 10.1200/JCO.2004.07.184.
    1. Sutton G, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol. Oncol. 2005;97:755–763. doi: 10.1016/j.ygyno.2005.03.011.
    1. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh. Dtsch. Ges. Pathol. 1997;81:228–232.
    1. Cheung LW, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011;1:170–185. doi: 10.1158/-11-0039.
    1. Levine RL, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. 1998;58:3254–3258.
    1. McConechy MK, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J. Pathol. 2012;228:20–30.
    1. Byron SA, et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS ONE. 2012;7:e30801. doi: 10.1371/journal.pone.0030801.
    1. Urick ME, et al. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 2011;71:4061–4067. doi: 10.1158/0008-5472.CAN-11-0549.
    1. Zighelboim I, et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J. Clin. Oncol. 2007;25:2042–2048. doi: 10.1200/JCO.2006.08.2107.
    1. Kuhn E, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J. Natl. Cancer Inst. 2012;104:1503–1513. doi: 10.1093/jnci/djs345.
    1. Le Gallo M, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nature Genet. 2012;44:1310–1315. doi: 10.1038/ng.2455.
    1. Salvesen HB, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc. Natl Acad. Sci. USA. 2009;106:4834–4839. doi: 10.1073/pnas.0806514106.
    1. Cowin PA, et al. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res. 2012;72:4060–4073. doi: 10.1158/0008-5472.CAN-12-0203.
    1. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature487, 330–337 (2012)
    1. Govindan R, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150:1121–1134. doi: 10.1016/j.cell.2012.08.024.
    1. Pleasance ED, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463:191–196. doi: 10.1038/nature08658.
    1. Palles C, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nature Genet. 2013;45:136–144. doi: 10.1038/ng.2503.
    1. Bartosch C, et al. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv. Anat. Pathol. 2011;18:415–437. doi: 10.1097/PAP.0b013e318234ab18.
    1. Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA. 1999;96:8681–8686. doi: 10.1073/pnas.96.15.8681.
    1. Hinoue T, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012;22:271–282. doi: 10.1101/gr.117523.110.
    1. Noushmehr H, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510–522. doi: 10.1016/j.ccr.2010.03.017.
    1. Shen R, Olshen AB, Ladanyi M. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics. 2009;25:2906–2912. doi: 10.1093/bioinformatics/btp543.
    1. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348:334–336. doi: 10.1038/348334a0.
    1. Ciriello G, Cerami E, Sander C, Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 2012;22:398–406. doi: 10.1101/gr.125567.111.
    1. Li J, Mizukami Y, Zhang X, Jo WS, Chung DC. Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3β. Gastroenterology. 2005;128:1907–1918. doi: 10.1053/j.gastro.2005.02.067.
    1. Zorn AM, et al. Regulation of Wnt signaling by Sox proteins: XSox17 α/β and XSox3 physically interact with β-catenin. Mol. Cell. 1999;4:487–498. doi: 10.1016/S1097-2765(00)80200-2.
    1. Sinner D, et al. Sox17 and Sox4 differentially regulate β-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol. Cell. Biol. 2007;27:7802–7815. doi: 10.1128/MCB.02179-06.
    1. Pollock PM, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 2007;26:7158–7162. doi: 10.1038/sj.onc.1210529.
    1. Fleming GF, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2010;116:15–20. doi: 10.1016/j.ygyno.2009.09.025.
    1. Vaske CJ, et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics. 2010;26:i237–i245. doi: 10.1093/bioinformatics/btq182.
    1. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature490, 61–70 (2012)
    1. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature474, 609–615 (2011)
    1. Clarke BA, Gilks CB. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J. Clin. Pathol. 2010;63:410–415. doi: 10.1136/jcp.2009.071225.
    1. Yemelyanova A, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am. J. Surg. Pathol. 2009;33:1504–1514. doi: 10.1097/PAS.0b013e3181ac35f5.
    1. Gilks CB, Oliva E, Soslow RA. Poor inter-observer reproducibility in the diagnosis of high-grade endometrial carcinoma. Am. J. Surg. Pathol. 2012;91:248A.
    1. Mermel CH, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:R41. doi: 10.1186/gb-2011-12-4-r41.
    1. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics. 2010;11:367. doi: 10.1186/1471-2105-11-367.
    1. Houseman EA, et al. Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of beta distributions. BMC Bioinformatics. 2008;9:365. doi: 10.1186/1471-2105-9-365.
    1. Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl Acad. Sci. USA. 2004;101:4164–4169. doi: 10.1073/pnas.0308531101.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe